Aprea Therapeutics (APRE) Enterprise Value (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Enterprise Value of -$46.5 million for Q1 2026, down 141.06% year-over-year from $113.2 million in Q1 2025, and down 218.28% quarter-over-quarter from -$14.6 million in Q4 2025.
Aprea Therapeutics (APRE) Enterprise Value (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Enterprise Value for 9 consecutive years, with -$46.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 141.06% year-over-year to -$46.5 million; the TTM figure through Mar 2026 stood at -$46.5 million (down 141.06% YoY), while the FY2025 annual figure was -$14.6 million, up 36.11% from the prior year.
- Enterprise Value fell to -$46.5 million in Q1 2026 per APRE's latest filing, from -$14.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$13.7 million in Q3 2025 and bottomed at -$47.7 million in Q1 2022.
- Historically, Enterprise Value has averaged -$27.9 million across 5 years, with a median of -$27.7 million in 2023.
- Annual changes were most pronounced in 2025 — Enterprise Value soared 47.74% — and 2026, when it slumped 141.06%.
- Aprea Therapeutics' Enterprise Value stood at -$28.8 million in 2022, then increased by 24.94% to -$21.6 million in 2023, then slipped by 5.75% to -$22.8 million in 2024, then soared by 36.11% to -$14.6 million in 2025, then sank by 218.28% to -$46.5 million in 2026.
- Business Quant data shows APRE's Enterprise Value at -$46.5 million in Q1 2026, -$14.6 million in Q4 2025, and -$13.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 2.12 Bn |
| 10 | Aprea Therapeutics | 33.32 Mn | 33.32 Mn | - | -41.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.23 Mn |
| Mar 31, 2026 | -46.47 Mn |
| Dec 31, 2025 | -14.60 Mn |
| Sep 30, 2025 | -13.72 Mn |
| Jun 30, 2025 | -16.50 Mn |
| Mar 31, 2025 | -19.28 Mn |
| Dec 31, 2024 | -22.85 Mn |
| Sep 30, 2024 | -26.25 Mn |
| Jun 30, 2024 | -28.69 Mn |
| Mar 31, 2024 | -32.37 Mn |
| Dec 31, 2023 | -21.61 Mn |
| Sep 30, 2023 | -25.35 Mn |
| Jun 30, 2023 | -27.69 Mn |
| Mar 31, 2023 | -31.00 Mn |
| Dec 31, 2022 | -28.79 Mn |
| Sep 30, 2022 | -33.11 Mn |
| Jun 30, 2022 | -39.06 Mn |
| Mar 31, 2022 | -47.65 Mn |
| Dec 31, 2021 | -53.08 Mn |
| Sep 30, 2021 | -61.43 Mn |